Minimal residual disease in acute myeloid leukemia: coming of age.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Hematology. American Society of Hematology. Education Program

• Publication date

  2012-12-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/asheducation-2012.1.35PMID 23233558
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunobiology of Acute Leukemia

  2013cited by this paper
• Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.

  2012cited by this paper
• Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets.

  2012cited by this paper
• Lessons Learned from the Investigational Device Exemption Review of Children's Oncology Group Trial AAML1031

  2012cited by this paper
• The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse

  2012cited by this paper
• [Dendritic cell-based therapeutic vaccination for acute myeloid leukemia].

  2012cited by this paper
• A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia.

  2012cited by this paper
• Vaccination thérapeutique à base de cellules dendritiques contre la leucémie aiguë myéloïde

  2012cited by this paper
• Next‐generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3‐ITD or NPM1 mutations

  2012cited by this paper
• Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia.

  2012cited by this paper
• Acute Myeloid Leukemia: Focus on Novel Therapeutic Strategies

  2012cited by this paper
• DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications.

  2012cited by this paper
• Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia.

  2012cited by this paper
• Towards individualized follow-up in adult acute myeloid leukemia in remission.

  2011cited by this paper
• Prevention and treatment of acute myeloid leukemia relapse after allogeneic stem cell transplantation

  2011cited by this paper
• Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.

  2011cited by this paper
• Recent Advance in Antigen-Specific Immunotherapy for Acute Myeloid Leukemia

  2011cited by this paper
• Biology, risk stratification, and therapy of pediatric acute leukemias: an update.

  2011cited by this paper
• Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia?

  2011cited by this paper
• Monitoring of minimal residual disease in acute myeloid leukemia: methods and best applications.

  2011cited by this paper
• Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms

  2011cited by this paper
• Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.

  2011cited by this paper
• Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse

  2011cited by this paper
• Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy.

  2011cited by this paper
• Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

  2011cited by this paper
• Novel approaches to the treatment of acute myeloid leukemia.

  2011cited by this paper
• Minimal residual disease in acute myeloid leukemia: already predicting a safe haven?

  2010cited by this paper
• Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol

  2010cited by this paper
• High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine.

  2010cited by this paper
• The role of multiparameter flow cytometry for disease monitoring in AML.

  2010cited by this paper
• Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia.

  2010cited by this paper
• Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

  2010cited by this paper
• Multi-parameter fluorescence-activated cell sorting and analysis of stem and progenitor cells in myeloid malignancies.

  2010cited by this paper
• Novel Approaches to Prevent Leukemia Relapse Following Allogeneic Hematopoietic Cell Transplantation

  2010cited by this paper
• High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event‐free survival

  2009cited by this paper
• Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study

  2009cited by this paper
• Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia

  2009cited by this paper
• Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.

  2009cited by this paper
• What do we mean by sensitivity when we talk about detecting minimal residual disease?

  2008cited by this paper
• Leading article

  2008cited by this paper
• Development of minimal residual disease-directed therapy in acute myeloid leukemia.

  2008cited by this paper
• Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.

  2006cited by this paper
• Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]

  2006cited by this paper
• Minimal residual disease in acute myeloid leukemia is predicted by P-glycoprotein activity but not by multidrug resistance protein activity at diagnosis

  2003cited by this paper
• Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia.

  2003cited by this paper
• Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia.

  2002cited by this paper
• Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification.

  2001cited by this paper

• Detection of MRD positivity as an indicator of CNS relapse in AML and therapeutic approach

  2025cites this paper
• Isolation of acute myeloid leukemia blasts from blood using a microfluidic device.

  2024cites this paper
• FLT4 as a marker for predicting prognostic risk of refractory acute myeloid leukemia

  2023cites this paper
• Pharmacological inhibition of Carbonic Anhydrase IX and XII to enhance targeting of acute myeloid leukaemia cells under hypoxic conditions

  2021cites this paper
• Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT

  2021cites this paper
• The prognostic impact of Wilms tumor-1 polymorphism (rs16754) and human myeloid inhibitory C-type lectin-like receptor expression in cytogenetically normal-acute myeloid leukemia

  2021cites this paper
• Ultrasensitive quantitation of genomic chimerism by single-molecule molecular inversion probe capture and high throughput sequencing of copy number deletion polymorphisms.

  2021cites this paper
• Measurable residual disease monitoring provides insufficient lead-time to prevent morphological relapse in the majority of patients with core-binding factor acute myeloid leukemia

  2020cites this paper
• Evaluation of dsDNA from extracellular vesicles (EVs) in pediatric AML diagnostics

  2020cites this paper
• Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment

  2020cites this paper
• Prognostic significance of CD56 and CD7 in acute myeloid leukaemia and their outcome.

  2020cites this paper
• Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use

  2020cites this paper
• Detection of AML-specific mutations in pediatric patient plasma using extracellular vesicle–derived RNA

  2019cites this paper
• Time-Delayed Integration-Spectral Flow Cytometer (TDI-SFC) for Low-Abundance-Cell Immunophenotyping.

  2019cites this paper
• Induction and Therapeutic Targeting of Human NPM1c+ Myeloid Leukemia in the Presence of Autologous Immune System in Mice

  2019cites this paper
• Ultrasensitive Detection of Chimerism by Single-Molecule Molecular Inversion Probe Capture and High-Throughput Sequencing of Copy Number Deletion Polymorphisms.

  2018cites this paper
• Impact of Day 14 Bone Marrow Biopsy on Re-Induction Decisions and Prediction of a Complete Response in Acute Myeloid Leukemia Cases

  2018cites this paper
• Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.

  2018cites this paper
• Discovering Rare Hematopoietic Clones Harboring Leukemia-Associated Mutations Using Error-Corrected Sequencing

  2018cites this paper
• Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia

  2017cites this paper
• Methods of Detection of Measurable Residual Disease in AML

  2017cites this paper
• 多参数流式细胞术检测急性白血病及浆细胞肿瘤微小残留病中国专家共识（2017年版）

  2017cites this paper
• Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes

  2017cites this paper
• Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.

  2017cites this paper
• Can Minimal Residual Disease Determination in Acute Myeloid Leukemia Be Used in Clinical Practice?

  2017cites this paper
• Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis

  2017influential citation
• Hematopoietic Cell Transplants: Concepts, Controversies, and Future Directions

  2017cites this paper
• Detection of DNMT3A R882 mutations in patients with acute myeloid leukaemia

  2017cites this paper
• [Effect of minimal residual disease monitoring by multiparameter flow cytometry pre-conditioning on prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].

  2017cites this paper
• Should patients with acute myeloid leukemia and measurable residual disease be transplanted in first complete remission?

  2017cites this paper
• Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia.

  2016cites this paper
• Evaluation of Minimal Residual Disease in Acute Myeloid Leukemia with NPM1 Marker

  2016cites this paper
• Should acute myeloid leukemia patients with actionable targets be offered investigational treatment after failing one cycle of standard induction therapy?

  2016cites this paper
• Stem Cell Modeling of Core Binding Factor Acute Myeloid Leukemia

  2016cites this paper
• Correlation of NPM1 Type A Mutation Burden With Clinical Status and Outcomes in Acute Myeloid Leukemia Patients With Mutated NPM1 Type A

  2016cites this paper
• Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?

  2016cites this paper
• Plasma-derived exosomes in acute myeloid leukemia for detection of minimal residual disease: are we ready?

  2016cites this paper
• Stanniocalcin1 gene expression in patients with acute leukemia: impact on response to therapy and disease outcome

  2016cites this paper
• Allo-HCT regimens with low toxicity needed in older patients with acute myeloid leukaemia.

  2016cites this paper
• DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling

  2016cites this paper
• Less Utilized Prognostic Markers in Acute Myeloid Leukemia: Abdullah M. Unapplied markers in AML

  2016cites this paper
• Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia

  2016cites this paper
• Microfluidics for the detection of minimal residual disease in acute myeloid leukemia patients using circulating leukemic cells selected from blood.

  2016cites this paper
• Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO‐AML 2004 study

  2016cites this paper
• CD274 promotes cell cycle entry of leukemia-initiating cells through JNK/Cyclin D2 signaling

  2016cites this paper
• Regulatory Informatics Reveals Minimal Residual Disease Trends in Hematologic Malignancies

  2016cites this paper
• Cell signaling in putative leukemic stem cells and blast population in acute myeloid leukemia

  2016cites this paper
• Dendritic cell development in haematological malignancies and neoplasia

  2015cites this paper
• Minimal residual disease-directed therapy in acute myeloid leukemia.

  2015cites this paper
• An Advanced Preclinical Mouse Model for Acute Myeloid Leukemia Using Patients' Cells of Various Genetic Subgroups and In Vivo Bioluminescence Imaging

  2015cites this paper
• Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia

  2015influential citation
• Emerging strategies for high-risk and relapsed/refractory acute myeloid leukemia: novel agents and approaches currently in clinical trials.

  2015cites this paper
• A multigene array for measurable residual disease detection in AML patients undergoing SCT

  2015cites this paper
• Reduced-intensity conditioned allogeneic SCT in adults with AML

  2015cites this paper
• Complex karyotype, older age, and reduced first‐line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long‐term follow‐up

  2015cites this paper
• Introducing minimal residual disease in acute myeloid leukemia

  2015cites this paper
• Minimal Residual Disease in AML: Why Has It Lagged Behind Pediatric ALL?

  2015cites this paper
• In vitro studies on anti-leukemic effects of tetracycline's analogues and cyclophosphamide

  2015cites this paper
• Association BetweenMutation Clearance After Induction Therapy andOutcomes in AcuteMyeloid Leukemia

  2015cites this paper
• Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia.

  2015cites this paper
• Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia.

  2015cites this paper
• "This is the peer reviewed version of the following article: “Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up”

  2015cites this paper
• Minimal Residual Disease in Acute Myeloid Leukemia

  2014cites this paper
• Targeted Next-Generation Sequencing at Copy-Number Breakpoints for Personalized Analysis of Rearranged Ends in Solid Tumors

  2014cites this paper
• Nucleic Acids as Molecular Diagnostics in Hematopoietic Malignancies – Implications in Diagnosis, Prognosis, and Therapeutic Management

  2014cites this paper
• Clustered precursors in bone marrow sections predict early relapse in patients with acute myeloid leukemia within hematologic remission

  2014cites this paper
• Molecular characterization of the rare translocation t(3;10)(q26;q21) in an acute myeloid leukemia patient

  2014cites this paper
• Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing

  2014cites this paper
• Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse

  2014cites this paper
• Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future

  2014cites this paper
• Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.

  2014cites this paper
• Immunophenotyping as Biomarker Platform in Acute Leukemia

  2014cites this paper
• Minimalna choroba resztkowa w ostrych białaczkach u dzieci i dorosłych

  2014cites this paper
• A new dawn for gemtuzumab ozogamicin?

  2014cites this paper
• Relapse assessment following allogeneic SCT in patients with MDS and AML

  2014cites this paper
• hMICL and CD123 in combination with a CD45/CD34/CD117 backbone – a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia

  2014cites this paper
• Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse

  2014cites this paper
• Bifunctional nanoparticles for surface-enhanced Raman spectroscopy-based leukemia biomarker detection

  2014cites this paper
• Surface Enhanced Raman Spectroscopy-Based Method for Leukemia Biomarker Detection Using Magnetic Core @ Gold Shell Nanoparticles

  2014cites this paper
• Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning.

  2014cites this paper
• Adult Acute Myeloid Leukemia Long-term Survivors.

  2014cites this paper
• Diagnosing and following adult patients with acute myeloid leukaemia in the genomic age

  2014cites this paper
• Reprint of: Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.

  2014cites this paper
• Hematopoietic stem cell transplantation and immunotherapy for pediatric acute myeloid leukemia: an open challenge

  2014cites this paper
• Aldehyde dehydrogenases in acute myeloid leukemia

  2014cites this paper
• Polymer nanopillar-gold arrays as surface-enhanced Raman spectroscopy substrate for the simultaneous detection of multiple genes.

  2014cites this paper
• Dendritic Cell-Based Immunotherapy for Myeloid Leukemias

  2013cites this paper
• Minimal residual disease testing in acute leukemia

  2013cites this paper
• Minimal residual disease in acute myeloid leukaemia

  2013cites this paper
• Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.

  2013cites this paper
• Immunobiology of Acute Leukemia

  2013cites this paper
• Acute myeloid leukemia - Apoptotic signalling and gene expression associated with treatment response

  2013cites this paper
• Acute myeloid leukemia: 2013 update on risk‐stratification and management

  2013cites this paper
• Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation

  2013cites this paper
• Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML

  2013cites this paper
• High-risk acute myelogenous leukemia: treatment today ... and tomorrow.

  2013cites this paper
• Acute myeloid leukemia : apoptotic signalling and gene expression associated with treatment response

  2013cites this paper
• When it comes to MRD, AML ≠ ALL.

  2012cites this paper
• The Detection and Significance of Minimal Residual Disease

  2012cites this paper
• Evidence-based Focused Review Minimal Residual Disease–directed Therapy in Acute Myeloid Leukemia Literature Search Strategy). Recommendations Were Developed Based on the Grading of Recommendations Assessment Development and Evalu- Ation System (table 1). Search Results and Discussion

  year unknowncites this paper